



UroGen to Present at 38th Annual J.P. Morgan Healthcare Conference

January 8, 2020

NEW YORK--(BUSINESS WIRE)--Jan. 8, 2020-- UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options, today announced that Liz Barrett, President and Chief Executive Officer, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2020 at 1:30 PM Pacific Time. The event will be held in San Francisco at the Westin St. Francis.

A live audio webcast of the event will be available on the Investors section of UroGen's website, www.urogen.com. A replay of the webcast will be available on the website for approximately two weeks.

About UroGen Pharma Ltd.

UroGen is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patients deserve better options. UroGen has developed RTGel™ reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs. UroGen's sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen's lead investigational candidates, UGN-101 (mitomycin gel) for instillation, and UGN-102 (mitomycin gel) for intravesical instillation, are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial cancer and low-grade non-muscle invasive bladder cancer, respectively. UroGen is headquartered in New York, NY with operations in Israel. Visit www.urogen.com to learn more or follow us on Twitter, [@UroGenPharma](https://twitter.com/UroGenPharma).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20200108005162/en/>

Source: UroGen Pharma Ltd.

INVESTOR CONTACT:

Kate Bechtold
Senior Director, Investor Relations
Kate.Bechtold@urogen.com
914-552-0456

MEDIA CONTACT:

Alice Sofield
BCW-UroGen@bcw-global.com
703-861-565